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ABSTRACT
Recent outbreaks of human coronaviruses, officially named severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), have put health authorities 
worldwide on a high alert. Firstly emerged in the city of Wuhan, China, SARS-
CoV-2 infection is rapidly escalating into a global pandemic. It is first thought 
as the result of a zoonotic transmission event, similar to the previous epidemic 
of coronaviruses. However, a continuously increasing number of confirmed 
cases indicates that the virus gains capacity of efficient human-to-human 
transmission. Soon after the pandemic is arising, many efforts are focused 
on identifying the origin of SARS-CoV-2 infection in the human population. 
Current evidence suggests that the virus is probably derived from bat or 
pangolin coronaviruses as the natural host. Whether intermediate host(s) exist 
in the transmission cascade from bat or pangolin to humans is, to a great extent, 
elusive. This information is essential as the basis for infection prevention and 
control measures. In this review, we discuss our recent understanding of SARS-
CoV-2 biology, highlighting its origin and molecular evolution.
ABSTRAK
Saat ini, kita sedang menghadapi wabah yang disebabkan oleh human corona 
virus, yang secara resmi diberi nama severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Wabah ini medapatkan perhatian yang luas 
dari berbagai institusi kesehatan di seluruh dunia. Dilaporkan pertama kali 
terjadi di kota Wuhan, Cina, wabah SARS-CoV-2 secara cepat telah menyebar 
ke banyak negara dan berkembang menjadi pandemi. Diduga awalnya bahwa 
virus SARS-CoV-2 ini berasal dari transmisi hewan kemanusia, sama seperti 
wabah coronaviruses sebelumnya. Akan tetapi, jumlah kasus terkonfirmasi 
yang semakin meningkat, menunjukkan indikasi bahwa virus SARS-CoV-2 
telah memiliki kapasitas untuk menular secara efektif dari manusia ke 
manusia. Segera setelah wabah terjadi, berbagai studi difokuskan untuk 
melacak asal urus virus SARS-CoV-2 sebelum menginfeksi manusia. Bukti-
bukti terkini menunjukkan bahwa SARS-CoV-2 kemungkinan berasal dari 
coronaviruses yang bersirkulasi di bats (kelelawar) atau pangolins. Apakah 
terdapat intermediate host antara kelelawar atau pangolins dan manusia, 
masih belum jelas. Informasi semacam ini sangat penting sebagai dasar 
tindakan pencegahan dan pengendalian wabah. Pada artikel ini, kami 
membahas tentang biologi virus SARS-CoV-2, dengan fokus pada asal usul dan 
evolusi virus tersebut.
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INTRODUCTION
Coronaviruses (CoVs) are a large 
family of RNA viruses infecting humans 
and many different animal species, 
including bats, swine, camels, cats, 
dogs, and other wildlife animals. In 
animals, CoVs may cause a variety of 
respiratory, gastrointestinal, hepatic, 
and neurologic infections with different 
clinical severity. For a long period, it 
has been recognized four strains of 
human CoVs (HCoV-NL63, HCoV-229E, 
HCoV-OC43, and HKU1), which cause 
only mild upper respiratory infections 
in immunocompetent individuals with 
unknown fatalities. Therefore, they are 
first considered as low pathogenic viruses 
in humans.1 However, the emergence 
of two novel human CoV strains 
responsible for worldwide outbreaks, 
i.e., severe acute respiratory syndrome 
CoV (SARS-CoV) (2002) and Middle East 
respiratory syndrome CoV (MERS-CoV) 
(2012), highlights the characteristics of 
CoV as highly pathogenic viruses that 
potentially cause lethality in the human 
population.2,3
More than 8,000 cases were 
identified during the SARS-CoV outbreak 
firstly emerged in Guangdong province, 
China, with about 774 fatalities (±10% 
case fatality rate, CFR). Since then, SARS-
CoV has been successfully contained and 
eradicated.4 In 2012, MERS-CoV outbreak 
firstly emerged in Jeddah, Saudi Arabia5, 
more than 2,400 cases were detected 
with ±34% CFR. In contrast to SARS-CoV, 
MERS-CoV continuously re-emerges 
through sporadic cases both in the 
community and in the hospital.4
Less than 20 years after the first 
deadly SARS-CoV outbreak, another crisis 
of viral pneumonia was recently emerged 
in the city of Wuhan, China.6,7 The third 
highly pathogenic human CoV, officially 
named as SARS-CoV-2,8 has been quickly 
identified as the causative agent of this 
rapidly spreading coronavirus disease 
2019 (COVID-19).6 SARS-CoV-2 has ±80% 
genomic similarity with SARS-CoV, hence 
its name.7 Both viruses have also been 
suggested to evolve from SARS-related 
CoV (SARSr-CoV) circulating in bats and 
employ the similar cell entry receptor 
(angiotensin-converting enzyme II, 
ACE2).7 Despite these similarities, the 
pandemic profile is different, in terms 
of its level of adaptation, virulence and 
transmissibility.9 It is currently estimated 
that the average basic reproduction 
number (R0) of  SARS-CoV-2 is 3.28 (median 
2.79), indicating that the confirmed 
cases will continuously increase.10 About 
four months since the beginning of the 
outbreak, by 26 April 2020, COVID-19 
has been confirmed in more than 2,8 
million cases worldwide. Moreover, 
193,710 deaths were reported in more 
than 200 countries and territories.11 We 
here discussed our recent understanding 
of SARS-CoV-2 biology, highlighting its 
origin and molecular evolution.
DISCUSSION
The molecular biology of SARS-CoV-2
CoVs are enveloped, single-
strand, positive-sense RNA viruses of 
approximately 26-32 kilobases (kb) in 
length, and thus it is known as the largest 
RNA virus.12 In addition, 5’-capped and 
poly (A) tail are present on the 5’- and 
3’-end of the genome, respectively. CoVs 
form spherical viral particles of 100-160 
nm in diameter. The viral membrane is 
composed of the spike (S) glycoprotein, 
the membrane (M) glycoprotein, and 
the envelope (E) protein, surrounding 
a flexible nucleocapsid (N) (FIGURE 
1A).13 CoVs belong to the family of 
Coronaviridae, within the subfamily of 
Coronavirinae. It is then further divided 
into Alpha-(α), Beta-(β), Gamma-(γ), and 
Delta-(δ) coronavirus based on serologic, 
genomic structures, and phylogenetic 
relationships.The four strains of “low 
pathogenic” coronavirus belong to the 
genus of Alphacoronavirus subgroup 
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1b (HCoV-NL63 and HCoV-229E) and 
Betacoronavirus sub group 2a (HCoV-
OC43 and HCoV-HKU1).2 Interestingly, all 
three strains of highly pathogenic CoVs 
(SARS-CoV, MERS-CoV, and SARS-CoV-2) 
cluster together within the subgroup 2b 
of Betacoronavirus genus.14
FIGURE 1. A. Coronavirus viral particles consist of four structural proteins, 
i.e., spike (S), envelope (E), membrane (M), and nucleocapsid (N). 
The S protein forms a layer of glycoproteins that protrude from 
the envelope. B. A large portion of the genome of SARS-CoV, MERS-
CoV, and SARS-CoV-2 is made up of a single open reading frame 1ab 
(orf1ab). This gene encodes a “giant” polyprotein (pp), pp1ab, which 
is further cut off by two viral-derived proteases to release 15 non-
structural proteins (nsp) for SARS-CoV-2 and 16 nsp for SARS-CoV and 
MERS-CoV. Another orf (orf1a) is also generated by a programmed 
ribosomal frameshifting during translation process in the ribosome. 
A single nsp (nsp11) is missing in the genome of SARS-CoV-2. The 
remaining 3’-end of the genome encodes the structural protein S, E, 
M, and N. Eight (for SARS-CoV and SARS-CoV-2) or five (for MERS-CoV) 
open reading frames (ORF) encoding so-called accessory proteins 
are interspersed between and within these structural protein-coding 
regions.
The genomic structure of SARS-CoV-2 
The basic genomic structure of SARS-
CoV-2 is similar with the other CoVs within 
the subgroup 2b of Betacoronavirus 
genus (FIGURE 1B).14 A large portion of 
the genome starting from its 5’-end is 
made up by a single open reading frame 
1ab (orf1ab). This gene encodes a “giant” 
polyprotein, pp1ab, which is further 
cut off by two viral-derived proteases 
to release 15 non-structural proteins 
(nsp, nsp1-nsp10 and nsp12-nsp16).15 
Another orf (orf1a) is also generated by 
a programmed ribosomal frameshifting, 
encoding pp1a protein which is further 
cleaved into ten non-structural proteins 
(nsp1-nsp10).15 Those proteins are mainly 
involved in replication and transcription 
of the genome in the early phase of the 
viral life cycle in the infected cells.16 The 
remaining 3’-end of the genome encodes 
the structural protein S, E, M, and N. Eight 
open reading frames (ORF) encoding so-
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called accessory proteins (3a, 3b, p6, 7a, 
7b, 8b, 9b, and orf14) are interspersed 
between and within these structural 
protein-coding regions.15 These genes 
are dispensable for virus replication, 
yet they are pivotal for viral-host 
interactions, including counteracting the 
host innate immunity.16 Analysis of SARS-
CoV-2 published sequences revealed that 
its genome shares 79.5% similarity to 
former SARS-CoV.7
The host receptor usage of SARS-CoV-2
It has been shown that SARS-CoV-2 
employs ACE2 as the cell entry receptor, 
similar to SARS-CoV.17,18 SARS-CoV-2 initial 
attachment to target cells is mediated 
by binding S protein to ACE2. Thus, the 
S glycoprotein plays an essential role in 
determining viral tropism, cross-species 
transmission, and infectivity.2
The S glycoprotein is structurally 
composed of two subunits, S1 and S2. 
The S1 subunit contains a receptor-
binding domain (RBD) responsible for 
engagement to ACE2 located on the 
upper part of S protein. Indeed, RBD 
is the most variable part of the CoV 
genome. This phenomenon tends to be 
common for the virus in general since 
it is the region that obtains continuous 
evolutionary pressure from the host 
immune system. At the lower part of S 
protein, there is a relatively conserved 
S2 sub-unit that function as fusion 
machinery with the cellular membrane, 
and thus, it is important for entry 
process.19 Noteworthy, SARS-CoV-2 S 
protein-mediated cell entry was potently 
blocked by murine-derived SARS-CoV S 
polyclonal antibodies. This mechanism 
indicates that targeting the conserved 
region of S protein by cross-neutralizing 
antibodies is one of the potential 
strategies to develop vaccines against 
SARS-CoV-2.19
As previously mentioned, 
engagement of S protein to ACE2 is crucial 
for entry process, like a lock and key 
mechanism. However, this engagement 
is not sufficient for viral entry. Another 
second feature is also needed, i.e., 
proteolytic cleavage event executed 
by cellular protease, transmembrane 
protease serine 2 (TMPRSS2).18 This 
protease cleaves the RBD of S protein to 
separate from the fusion domain. This 
event drives fusion of viral membrane 
with the host’s cellular membrane.20 It 
was reported that constitutive expression 
TMPRSS2 enhanced susceptibility of 
VeroE6 cell line to SARS-CoV-2 infection.21 
Indeed, the S protein of SARS-CoV-2 is a 
classic class I fusion protein, similar to 
hemagglutinin (HA) protein of influenza 
virus.22
Previous mutational analysis 
demonstrated that six amino acid 
residues are critical for binding to human 
ACE2. Surprisingly, five substitutions 
were identified among those six residues 
in SARS-CoV-2 genome compared with 
SARS-CoV.15 Structural studies and 
biochemical experiments showed that 
the RBD of SARS-CoV-2 binds with high 
affinity to human ACE2, although this 
interaction is not optimal.17 These studies 
suggest that S protein of SARS-CoV-2 is 
most likely naturally selected on humans 
or other species with high homology to 
human ACE2. Other features of S protein 
of SARS-CoV-2 that result in more 
optimal binding to human ACE2 remain 
to be elucidated to give insight into its 
capacity of efficient human-to-human 
transmission.23
Another unique feature SARS-CoV-2 
spike glycoprotein is the acquisition 
of a polybasic cleavage site (PRRAR), 
which allows more effective cleavage by 
another unidentified cellular protease(s). 
This prominent feature was not found 
in SARS-CoV and SARSr-CoV.23 This 
cleavage site is located at the junction of 
S1 and S2 subunits.19 Previous studies in 
influenza virus found that acquisition 
of this feature converts low-pathogenic 
into high-pathogenic influenza viruses.24 
Current pandemic situations suggest that 
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SARS-CoV-2 is less pathogenic yet more 
transmissible than SARS-CoV and MERS-
CoV.9 Therefore, further experiments are 
required to investigate the impact of the 
polybasic cleavage site on SARS-CoV-2 
pathogenicity and transmissibility.
SARS-CoV-induced ACE2 downregulation 
ACE2 is widely expressed in the 
gastrointestinal tract, heart, kidney, and 
lung, especially in type II alveolar cells.25 
It is also found on the oral cavity mucosa, 
particularly in the epithelial cells of the 
tongue.26 Its counterpart, ACE, is widely 
expressed on the surface of endothelial 
cells, particularly in the lungs. In 
cooperation with renin produced by the 
kidney, ACE and ACE2 are involved in 
the renin-angiotensin system (RAS). ACE 
mediates the conversion of angiotensin 
I to angiotensin II, which then induces 
the vasoconstriction of the blood flow. 
In contrast, ACE2 generates angiotensin 
from angiotensin II with a vasodilation 
effect. Thus, ACE and ACE2 regulate the 
homeostatic balance of vasoconstriction 
and vasodilation of the vascular system.25
It has been suggested that patients 
who are treated with ACE inhibitors 
(ACEIs) and angiotensin receptor 
blockers (ARBs) may be at increased 
risk of severe SARS-CoV-2 infection.27 
This is because both ACEIs and ARBs 
increase the expression of ACE2 in 
the cardiopulmonary circulation.28 
However, it has been shown that ACE2 
and angiotensin play a protective role 
from lung injury. Downregulation of 
pulmonary ACE2 was associated with 
acute lung injury, as characterized by 
increased vascular permeability, lung 
edema, inflammation, and reduced lung 
function.29-32 These phenomena reflect 
the dysfunction of the RAS system due to 
over accumulation of angiotensin II.33
The S protein of SARS-CoV 
downregulates ACE2 expression 
following initial attachment and fusion 
of the viral membrane, and thereby 
contributes to severe lung injury.32 
Therefore, ACE2-associated lung injury 
has been suggested to be involved in 
SARS-CoV pathogenesis.34 This SARS-CoV-
induced downregulation of ACE2 can be 
reversed by angiotensin receptor blocker 
(ARB) treatment that is commonly used in 
hypertension patients. It is also suggested 
that administration of soluble form of 
ACE2 may competitively bind to S protein 
to neutralize the virus and also rescue 
the cellular ACE2 levels.35,36 However, 
limited clinical data are available about 
the efficacy of ARBs and ACEIs in the 
treatment of SARS-CoV-2-induced lung 
injury.37 Since SARS-CoV-2 employs ACE2 
as a host cell entry receptor, it is possible 
that ACE2 is involved in the inflammatory 
response of SARS-CoV-2.34 However, 
the role of ACE2 in the pathogenesis of 
COVID-19 is poorly understood. Due to 
these conflicting mechanisms, careful 
pharmacoepidemiologic studies are 
urgently needed to investigate whether 
RAS inhibition improves or worsens the 
outcomes of COVID-19 patients.33
Evolution of SARS-CoV-2 and cross-
species transmission
Bat coronaviruses as the origin of 
SARS-CoV and MERS-CoV
Bats are were well-known to harbor 
highly pathogenic, emerging, or re-
emerging RNA viruses posing a great 
threat to human health, including 
bat lyssaviruses (Rabies virus) and 
henipaviruses (Hendra and Nipah 
viruses). Therefore, it is not surprising 
that bats have also been recognized as 
the natural reservoir of most, if not all, 
mammalian CoVs, including SARS-CoV 
and MERS-CoV.38 Earlier investigation of 
SARS outbreak (2003) identified SARS-
CoV and anti-SARS-CoV antibodies in the 
masked palm civet (Paguma larvata).39 
However, a large scale identification 
of both farmed and wild civets found that 
other animals were the source of SARS-CoV 
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transmission to civets.40,41 Besides, civets 
are not known as the natural host of CoVs. 
Thereafter, SARSr-CoV was identified 
in horseshoe bats (genus Rhinolophus), 
indicating a natural origin of human 
SARS-CoV and that civets are the most 
likely intermediate host for SARS-CoV.42 
It has been hypothesized that SARS-CoV 
in civets acquires new mutations before 
cross-transmission to humans.2 SARS-
CoV eradication from the intermediate 
animal reservoir (civets) is among one 
measure for a successful SARS-CoV 
containment and eradication during 
SARS-CoV pandemic in 2003.43
Epidemiologic investigations of 
the early cases of MERS-CoV revealed 
that most patients had contact histories 
with dromedary camels, suggesting 
zoonotic events.2 Phylogenetic analysis 
of MERS-CoV derived from human cases 
and dromedary camels showed that 
they were almost identical in sequence, 
indicating that humans and camels were 
infected with the same source of MERS-
CoV.2 Interestingly, anti-MERS-CoV 
antibodies were detected in archived 
serum samples of camels collected in 
1983.44 This suggests that the spillover 
event to camel already occurred at least 
30 years before the MERS outbreak. 
This study also suggests that MERS-CoV 
had circulated and adapted in camels 
for 30 years before it acquired unique 
characteristics that enable an efficient 
transmission to humans. More than 
ten bat species from two bat families, 
Vespertilionidae and Nycteridae, were 
found to harbor MERS-related CoVs 
(MERSr-CoVs), suggesting the original 
ancestor of human MERS-CoV.2
Bat or pangolin CoVs as the origin of 
SARS-CoV-2
Phylogenetic analysis of SARS-CoV-2 
and various CoVs from different hosts 
demonstrated that SARS-CoV-2 belong to 
the Betacoronavirusgenera.45 Thus, it is 
classified in the subgenus Sarbecovirus 
of the Betacoronavirus genus.6,14 Based on 
molecular clock analysis, its most recent 
common ancestor emerged around at the 
end of November 2019.46 At the amino 
acid levels, the similarity between SARS-
CoV-2 and former SARS-CoV is 76.47%.45
It is logical to suggest that bats are 
the natural hosts of SARS-CoV-2 based 
on its similarity with former SARS-
CoV. Indeed, initial sequence analyses 
demonstrated that SARS-CoV-2 was 
closely related to bat-derived SARSr-
CoVs (bat-SL-CoV-ZC45 and bat-SL-CoV-
ZXC21) originally identified in the city 
of Nanjing, China.6,47,48 However, SARS-
CoV-2 formed a monophyletic cluster 
different from these two CoV strains, 
suggesting that they are not the direct 
ancestors of SARS-CoV-2.6,47,48 In addition, 
it has been suggested that SARS-CoV-2 is a 
recombinant virus between bat CoVs and 
unknown CoV. This recombination event 
probably occurs in S protein recognizing 
the cell-surface receptor.47 All these 
findings suggest that SARS-CoV-2 share 
similar genetic information with bat 
CoVs and that bat SARS-like CoVs as the 
probable origin of SARS-CoV-2.46
It was subsequently identified 
that bat CoV strain RaTG13 had 96.2% 
overall genome sequence identity 
with SARS-CoV-2.49 Bat CoV RaTG13 
was found from Rhinolophusaffinis bat 
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sampled from Yunnan Province, China. 
However, bat CoV RaTG13 differs in the 
RBD with SARS-CoV-2. It shares 89% 
identity at amino acid level with SARS-
CoV-2.23 Importantly, four out of five key 
amino acid residues in the RBD of bat 
CoV RaTG13 were different with SARS-
CoV-2.49 These suggest that S protein of 
bat CoV RaTG13 may not bind efficiently 
to human ACE2. Thus indicating that 
they are not the direct ancestors of SARS-
CoV-2.
The second parental virus predicted 
to be the origin of SARS-CoV-2 is 
CoVs identified in Malayan pangolins 
(Manis javanica) obtained during anti-
smuggling operations in Guangdong and 
Guangxi, named as pangolin-CoVs.49,50 
Pangolins are among the sources of 
meat in a certain region in China.51 At 
the whole genome level, pangolin-CoV 
shares 91.02% sequence similarity with 
that of SARS-CoV-2. However, its RBD 
was predicted to interact with human 
ACE2. Surprisingly, five key amino acids 
in RBD are similar between pangolin-
CoV and SARS-CoV-2, while RaTG13 only 
has one identical residue.49,50,52 Since 
the sequence divergence at the whole 
genome level and also the absence of 
polybasic cleavage sites in pangolin-CoV, 
it is not likely that pangolin-CoVs are 
the intermediate host of SARS-CoV-2.53 
However, considering the fact that CoV 
infection in Manis javanica results in 
poor conditions, in contrast to bats, it is 
also possible that pangolins serve as the 
intermediate and not the natural host for 
SARS-CoV-2.52 A deeper study is urgently 
needed to clarify this issue.
Altogether, it is most likely that 
bats or pangolins serve as natural 
hosts of the newly identified SARS-
CoV-2. It is possible that the ancestral 
of SARS-CoV-2 directly cross to humans 
and acquires further adaptation (i.e., 
acquisition of polybasic cleavage site) 
in human population.23 There is also a 
possibility of the presence of unknown 
and unidentified intermediate hosts in 
the transmission cascade from bats or 
pangolins to humans. Epidemiologic 
investigations of pneumonia outbreaks 
in China showed that most of the initial 
patients (66%) were directly exposed to 
wildlife animals at the Huanan seafood 
market.54 This market sells fish and 
wildlife animals, including marmots and 
snakes.55 However, bats CoVs are not 
thought to infect humans directly since 
most bats in Wuhan are in a hibernating 
period in the late December and no 
bats were sold at Huanan market. Thus, 
intermediate host(s) may exist between 
bats or pangolin and humans (FIGURE 
2).56
An early study employing relative 
synonymous codon usage (RSCU) 
analysis showed that SARS-CoV-2 has 
similar synonymous codon usage with 
snakes, suggesting its potential as the 
intermediate host.47 However, this 
conclusion was disputed by another 
study.52 Besides, SARSr-CoVs have not 
identified yet in snakes. Therefore, 
there is no solid evidence up to this 
moment that snakes or other wildlife 
animals are responsible as intermediate 
hosts for SARS-CoV-2. Therefore, the 
identification of animal reservoirs 
serves as intermediate host(s) of SARS-
CoV-2 is essential to understand its 
spill over to human populations and 
to formulate proper containment 
measures. Possibilities of another source 
of infection are likely since a number of 
initial patients had no contact history 
with Huanan market.57
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FIGURE 2. Model of evolution and cross-species transmission of coronaviruses from 
bats. Five out of seven human coronaviruses are known to derive from bat 
coronaviruses. Bat-derived recombinant viruses are shown in mixed colors. 
Each color represents the ancestral virus circulating in the natural reser-
voir (bats). These recombinant viruses potentially lead to the cross-species 
transmission to intermediate hosts and finally to humans as end hosts. For 
SARS-CoV-2, whether pangolin serves as the intermediate host is unclear. 
Two other human coronaviruses (HCoV-OC43 and HCoV-HKU1) are likely 
originated from rodents (not shown). Severe acute diarrhea syndrome CoV 
(SADS-CoV) causes large outbreaks and fatal diseases in pigs, with no known 
transmission to the human population.
The evolution of SARS-CoV-2 in human 
populations
A chronological set of sequence 
of SARS-CoV strains isolated during 
the early, middle, and late phases of 
epidemic demonstrated continuous and 
dynamic mutational changes of SARS-
CoV following epidemic expansion in 
2003.58 It is generally estimated that 
mutation rates for RNA virus are about 
10-3 to 10-5. Surprisingly, in contrast to 
other RNA viruses, SARS-CoV possesses 
3’-5’ exonuclease activity encoded by 
nsp14. This nsp14-encoded protein 
serves as RNA proof-reading activity 
and consequently, lowering the error 
possibility during replication of RNA 
genome.59 Therefore, it is generally 
estimated that the mutation rates of 
SARS-CoV and other CoVs were about 2 x 
10-6.58 However, recent analysis suggests 
that the evolutionary rate of SARS-
CoV-2 is 6.58 x 10-3 substitution site per 
year.46 This suggests that although the 
virus does not frequently mutate, the 
high number of human infections has 
provided sufficient opportunity for such 
events.
Indeed, sequence analysis of different 
SARS-CoV-2 strains collected from 
various countries showed the presence 
of many mutations and deletions in the 
genome, indicating a rapid evolution of 
the virus during this current pandemic.60 
Phylogenetic study revealed that SARS-
CoV-2 across the world have evolved 
into three variants (A, B and C variants) 
based on amino acid differences, 
suggesting a dynamic evolution of 
SARS-CoV-2 following introduction to 
human population.61 All these results 
suggest that SARS-CoV-2 continuously 
evolves following its first introduction 
to the human population. Consequently, 
this event may influence its virulence, 
infectivity, and transmissibility.62
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CONCLUSIONS AND FUTURE 
PERSPECTIVES
The emergence of SARS-CoV-2 
infection, the responsible agent for 
COVID-19 pandemic, has put countries 
worldwide, on a high alert. Studies have 
been published to delineate the origin 
as well as the molecular characteristics 
of this newly emerging virus. Much 
information has been gained, yet more 
details need to be clarified. Sequence 
analysis of SARS-CoV-2 genome has 
shown that it is likely originated from 
bat or pangolin coronaviruses. However, 
how this cross-species transmission 
occurs, and further adaptation in 
humans requires further studies. Close 
and continuous monitoring of the virus 
during this pandemic crisis is highly 
required to keep track of the virus’ 
mutation and adaptation in humans 
as wells as its infectivity, pathogenicity, 
and transmissibility. Finally, studies of 
animal coronaviruses, especially bat 
coronaviruses, need to be continued in 
parallel for early detections and warning 
signs for the possibilities of future 
outbreaks.
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